STARGLO Dulled: Genentech’s Columvi Data Not Generalizable To US Patients, FDA Panel Says

The glofitamab trial results are not generalizable due to the small number of enrolled US lymphoma patients and adverse results across multiple endpoints for patients from non-Asian regions, the Oncologic Drugs Advisory Committee said.